Results 171 to 180 of about 1,123,126 (369)

Utilization of real‐world data in assessing treatment effectiveness for diffuse large B‐cell lymphoma

American Journal of Hematology, Volume 98, Issue 1, Page 180-192, January 2023., 2023
Abstract Direct comparisons of the effectiveness of the numerous novel therapies in the diffuse large B‐cell lymphoma (DLBCL) treatment landscape in a range of head‐to‐head randomized phase 3 trials would be time‐consuming and costly. Comparative effectiveness studies using real‐world data (RWD) represent a complementary approach.
Grzegorz Nowakowski, Matthew J. Maurer, James R. Cerhan, Debarshi Dey, Laurie H. Sehn   +4 more
wiley   +1 more source

LEUKEMIA—REPORT OF TWO CASES [PDF]

, 1915
Carl R. Steinke
openalex   +1 more source

Berberine is a Novel Mitochondrial Calcium Uniporter Inhibitor that Disrupts MCU‐EMRE Assembly

Advanced Science, EarlyView.
Berberine, a safe and FDA‐approved drug, is identified as a novel mitochondrial calcium uniporter (MCU) inhibitor. By disrupting MCU‐EMRE interaction, Berberine prevents mitochondrial calcium overload and protects against ischemia/reperfusion injury, offering a promising therapeutic strategy for diseases linked to mitochondrial calcium dysregulation ...
Haixin Zhao, Siqi Chen, Nian Cao, Wenjun Wu, Guangqin Liu, Jun Gao, Jiayi Chen, Ting Li, Dingyi Lu, Lingmin Zeng, Haizhen Zhu, Weina Zhang, Qing Xia, Teng Li, Tao Zhou, Xue‐Min Zhang, Ai‐Ling Li, Xin Pan   +17 more
wiley   +1 more source

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

American Journal of Hematology, Volume 98, Issue 2, Page 272-281, February 2023., 2023
Abstract Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there is a critical need for effective therapeutic strategies.
Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin Filshie, Olatoyosi Odenike, Anne Marie Watson, Ravitharan Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Wei‐Han Cheng, Ying Zhou, David Hoffman, Jason G. Harb, Jalaja Potluri, Guillermo Garcia‐Manero   +18 more
wiley   +1 more source

Ethnic Differences in the Incidence of Leukemia [PDF]

, 1957
Brian MacMahon, Ernest K. Koller
openalex   +1 more source

YC‐4‐3, a Novel Glycogen Synthase Kinase 3β Inhibitor, Alleviates the Endoplasmic Reticulum Stress of Macrophages in Primary Immune Thrombocytopenia

Advanced Science, EarlyView.
A patented GSK‐3β inhibitor (GSK‐3βi), new benzothiazepinone compounds (BTZs), YC‐4‐3, can modulate the inflammatory status of macrophages in primary immune thrombocytopenia (ITP), and improve the thrombocytopenia in murine ITP models by directly interacting with endoplasmic reticulum (ER) stress response.
Pengcheng Xu, Lili Ji, Yanxia Zhan, Yang Ou, Xia Shao, Xibing Zhuang, Fanli Hua, Feng Li, Hao Chen, Yong Chu, Yunfeng Cheng   +10 more
wiley   +1 more source

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis

, 2023
American Journal of Hematology, Volume 98, Issue 1, Page E15-E19, January 2023.
Meletios A. Dimopoulos, Philippe Moreau, Bradley Augustson, Nelson Castro, Tomas Pika, Sosana Delimpasi, Javier De la Rubia, Angelo Maiolino, Tony Reiman, Joaquin Martinez‐Lopez, Thomas Martin, Joseph Mikhael, Kwee Yong, Marie‐Laure Risse, Gaelle Asset, Sylvia Marion, Roman Hajek   +16 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia

American Journal of Hematology, Volume 98, Issue 2, Page 338-347, February 2023., 2023
Abstract Bruton tyrosine kinase (BTK) inhibitors have taken a central role in the management of patients with Waldenström macroglobulinemia and are the only agents approved by the Food and Drug Administration (FDA) to treat these patients. Although associated with high rates of durable responses, unmet needs with BTK inhibitor therapy include ...
Jorge J. Castillo, Christian Buske, Judith Trotman, Shayna Sarosiek, Steven P. Treon   +4 more
wiley   +1 more source

Induction of Allergic Contact Dermatitis in Patients with the Lymphoma-Leukemia Complex**From the Department of Dermatology (Donald M. Pillsbury, M.D., Director), School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

, 1958
William L. Epstein
openalex   +1 more source

The nitrogen mustards in the treatment of leukemia [PDF]

, 1949
Joseph H. Burchenal, W. P. Laird Myers, Lloyd F. Craver, David A. Karnofsky   +3 more
openalex   +1 more source